SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Clinical trial NCT05303519 · RECRUITING

Trial details

NCT number: NCT05303519
Sponsor: Nuvation Bio Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Glioma Astrocytoma, Grade IV IDH1-mutant Glioma Astrocytoma, IDH-Mutant, Grade 3 Astrocytoma, IDH-Mutant, Grade 4 Astrocytoma, IDH-Mutant, Grade 2 Oligodendroglioma Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Start date: 2023-06-05
Primary completion: 2028-12-01
Enrollment: 365

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.